In this study, we demonstrated STMN1 as a potential clinical therapeutic marker in ovarian cancer and successfully designed and constructed a PEG-coated nano delivery system based on MPDA, which co-loaded with PTX and siRNA (STMN1) for the combined therapy of ovarian cancer. The gene discussed is STMN1; the disease is ovarian carcinoma.